Dong-A Socio Holdings Co., Ltd. (000640.KS)
KRW 110000.0
(4.86%)
KRW 110000.0
(4.86%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 76.88 Billion KRW | 103.49% |
| 2022 | 37.85 Billion KRW | -38.51% |
| 2021 | 61.56 Billion KRW | -66.2% |
| 2020 | 182.14 Billion KRW | 244.82% |
| 2019 | 52.82 Billion KRW | 4.5% |
| 2018 | 50.54 Billion KRW | -5.29% |
| 2017 | 53.37 Billion KRW | -29.77% |
| 2016 | 75.99 Billion KRW | 18.08% |
| 2015 | 64.35 Billion KRW | 209.02% |
| 2014 | 20.82 Billion KRW | -38.09% |
| 2013 | 33.64 Billion KRW | -68.22% |
| 2012 | 105.84 Billion KRW | -6.76% |
| 2011 | 113.51 Billion KRW | -10.52% |
| 2010 | 126.85 Billion KRW | 25.05% |
| 2009 | 101.44 Billion KRW | 20.72% |
| 2008 | 84.03 Billion KRW | 10.88% |
| 2007 | 75.78 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 22.31 Billion KRW | 43.48% |
| 2024 Q1 | 15.54 Billion KRW | -2.87% |
| 2023 Q2 | 19.61 Billion KRW | 19.0% |
| 2023 Q1 | 16.48 Billion KRW | 850.09% |
| 2023 Q4 | 16 Billion KRW | -35.38% |
| 2023 FY | 77.03 Billion KRW | 103.49% |
| 2023 Q3 | 24.77 Billion KRW | 26.28% |
| 2022 Q1 | -2 Billion KRW | -111.37% |
| 2022 Q2 | 14.22 Billion KRW | 810.97% |
| 2022 Q3 | 22.43 Billion KRW | 57.65% |
| 2022 Q4 | -2.19 Billion KRW | -109.8% |
| 2022 FY | 37.85 Billion KRW | -38.51% |
| 2021 Q1 | 5.44 Billion KRW | -44.84% |
| 2021 Q2 | 18.37 Billion KRW | 237.33% |
| 2021 Q3 | 20.13 Billion KRW | 9.56% |
| 2021 Q4 | 17.6 Billion KRW | -12.58% |
| 2021 FY | 61.56 Billion KRW | -66.2% |
| 2020 Q2 | 14.2 Billion KRW | 61.2% |
| 2020 FY | 182.14 Billion KRW | 244.82% |
| 2020 Q1 | 8.81 Billion KRW | -29.86% |
| 2020 Q4 | 9.87 Billion KRW | -44.25% |
| 2020 Q3 | 17.71 Billion KRW | 24.7% |
| 2019 Q1 | 6.48 Billion KRW | -53.7% |
| 2019 FY | 52.82 Billion KRW | 4.5% |
| 2019 Q4 | 12.56 Billion KRW | -36.3% |
| 2019 Q3 | 19.72 Billion KRW | 40.38% |
| 2019 Q2 | 14.05 Billion KRW | 116.79% |
| 2018 Q2 | 20.95 Billion KRW | 276.97% |
| 2018 Q1 | 5.55 Billion KRW | -41.35% |
| 2018 FY | 50.54 Billion KRW | -5.29% |
| 2018 Q4 | 13.99 Billion KRW | 39.4% |
| 2018 Q3 | 10.04 Billion KRW | -52.07% |
| 2017 FY | 53.37 Billion KRW | -29.77% |
| 2017 Q4 | 9.47 Billion KRW | -45.75% |
| 2017 Q3 | 17.46 Billion KRW | -17.04% |
| 2017 Q2 | 21.05 Billion KRW | 292.06% |
| 2017 Q1 | 5.37 Billion KRW | -37.38% |
| 2016 Q2 | 40.75 Billion KRW | 189.28% |
| 2016 FY | 75.99 Billion KRW | 18.08% |
| 2016 Q4 | 8.57 Billion KRW | -31.78% |
| 2016 Q1 | 14.09 Billion KRW | -9.07% |
| 2016 Q3 | 12.57 Billion KRW | -69.15% |
| 2015 Q2 | 17.16 Billion KRW | 477.08% |
| 2015 FY | 64.35 Billion KRW | 209.02% |
| 2015 Q1 | 2.97 Billion KRW | -49.27% |
| 2015 Q4 | 15.49 Billion KRW | -46.05% |
| 2015 Q3 | 28.72 Billion KRW | 67.32% |
| 2014 FY | 20.82 Billion KRW | -38.09% |
| 2014 Q3 | 362.51 Million KRW | -96.04% |
| 2014 Q2 | 9.15 Billion KRW | 68.09% |
| 2014 Q4 | 5.86 Billion KRW | 1517.55% |
| 2014 Q1 | 5.44 Billion KRW | -59.97% |
| 2013 Q4 | 13.6 Billion KRW | 10.39% |
| 2013 FY | 33.64 Billion KRW | -68.22% |
| 2013 Q1 | 745.62 Million KRW | -99.06% |
| 2013 Q2 | 6.96 Billion KRW | 833.75% |
| 2013 Q3 | 12.32 Billion KRW | 77.04% |
| 2012 FY | 105.84 Billion KRW | -6.76% |
| 2012 Q1 | 16.17 Billion KRW | 0.0% |
| 2012 Q2 | 10.08 Billion KRW | -37.66% |
| 2012 Q3 | 12.61 Billion KRW | 25.11% |
| 2012 Q4 | 79.16 Billion KRW | 527.62% |
| 2011 FY | 113.51 Billion KRW | -10.52% |
| 2011 Q3 | 28.23 Billion KRW | -5.23% |
| 2011 Q1 | 30.34 Billion KRW | 0.0% |
| 2011 Q2 | 29.79 Billion KRW | -1.82% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 29.49 Billion KRW | 3.0% |
| 2010 FY | 126.85 Billion KRW | 25.05% |
| 2010 Q2 | 28.64 Billion KRW | 22.98% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 23.28 Billion KRW | 0.0% |
| 2009 Q3 | 28.28 Billion KRW | 31.51% |
| 2009 Q2 | 21.5 Billion KRW | 20.32% |
| 2009 Q1 | 17.87 Billion KRW | 0.0% |
| 2009 FY | 101.44 Billion KRW | 20.72% |
| 2009 Q4 | - KRW | -100.0% |
| 2008 FY | 84.03 Billion KRW | 10.88% |
| 2008 Q3 | 25.16 Billion KRW | 21.78% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q1 | 14.89 Billion KRW | 0.0% |
| 2008 Q2 | 20.66 Billion KRW | 38.72% |
| 2007 Q1 | 11.78 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 75.78 Billion KRW | 0.0% |
| 2007 Q2 | 19.14 Billion KRW | 62.4% |
| 2007 Q3 | 23.64 Billion KRW | 23.54% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -20990.232% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 196.631% |
| HANDOK Inc. | 12.57 Billion KRW | -511.199% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 3965.068% |
| Yuhan Corporation | 74.56 Billion KRW | -3.11% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -587.767% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 526.114% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 65.813% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -2415.714% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -435.745% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -12790.906% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -7877.224% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -184.416% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -20990.232% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 1091.248% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -1806.018% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 209.909% |
| JW Holdings Corporation | 143.66 Billion KRW | 46.486% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 243.926% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 68.823% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 23.351% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 262.224% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -1009.896% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -1088.091% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -780.522% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -20990.232% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -57.649% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 42.37% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 23.351% |
| Yuhan Corporation | 74.56 Billion KRW | -3.11% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -267.5% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -2366.217% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -78.816% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 23.351% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -275.319% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -39.913% |
| CKD Bio Corp. | -20.15 Billion KRW | 481.499% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -138.52% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -203.855% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -136.377% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 262.224% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -131.943% |
| Boryung Corporation | 68.26 Billion KRW | -12.619% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 305.036% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -435.745% |
| JW Lifescience Corporation | 32.09 Billion KRW | -139.571% |